On Monday, Illumina offered $8 billion to acquire GRAIL, an Illumina spin-out dedicated to early cancer testing. Early on, GRAIL merged with Cirina, a Hong Kong company that had developed the novel technology that GRAIL used as the cornerstone for its cancer test. Cirina was backed by Decheng Capital, a healthcare venture capital firm with offices in Silicon Valley and Shanghai . In an exclusive interview, Min Cui, PhD, Founder and Managing Partner of Decheng, told ChinaBio® Today about Decheng's long history with Cirina and how the company came to be part of the $8 billion Illumina-GRAIL deal. More details.... Stock Symbol: (NSDQ: ILMN) Share this with colleagues: // //